Sotalol hydrochloride is a potent noncardioselective β-adrenergic-blocking agent devoid of
intrinsic sympathomimetic and membrane-stabilizing actions1–6. Unlike other β-adrenergic …

Key safety parameters of sotalol were examined in 1,288 patients entered into recent
controlled trials of ventricular (85% of patients) or supraventricular arrhythmias (15%). Most …

This open, parallel-group study compares quinidine and sotalol treatment for maintenance
of sinus rhythm after direct current conversion of patients with chronic atrial fibrillation. The …

Sotalol, the most recently approved oral antiarrhythmic drug, has a unique pharmacologic
profile. Its electrophysiology is explained by nonselective β-blocking action as well as class …

Acute myocardial ischemia is one of the main causes of sudden cardiac death. The
mechanisms have been investigated primarily in experimental and computational studies …

The electromechanical effects of UK-68,798 (UK), a novel class III antiarrhythmic drug, were
studied in guinea pig and rat papillary muscles (PMs) and atria in vitro using conventional …

Objectives. This study evaluates the clinical efficacy of d, l-sotalol in patients with sustained
ventricular tachyarrhythmias. Background. D, l-sotalol is an important antiarrhythmic agent to …

The efficacy of antiarrhythmic drugs for terminating sustained ventricular tachycardia (VT)
has been disappointing. Lignocaine is the traditional drug but it is not very effective. Sotalol …

Dl-sotalol is a specific beta-adrenergic blocking agent that markedly lengthens cardiac
action potential duration. To determine whether d-sotalol, with little or no beta-blocking …

Synopsis Sotalol 1 is a β-adrenoceptor blocking agent devoid of intrinsic sympathomimetic
activity, membrane stabilising actions and cardioselectivity. It lengthens repolarisation and …